Skip to content
10-Q

Quarterly Report

Yew Bio-Pharm Group, Inc.

0001213900-19-023461

← back to feed
Filed
Nov 14, 2019 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2019 · Nov 14, 2019 51.7M sh
Short Term Debt Q3 2019 · Sep 30, 2019 $8.04M
Short Term Debt Q3 2019 · Dec 31, 2018 $5.76M
Cash And Equivalents Q3 2019 · Sep 30, 2019 $627.74K
Cash And Equivalents Q3 2019 · Dec 31, 2018 $521.67K
Cash And Equivalents Q3 2019 · Sep 30, 2018 $522.26K
Cash And Equivalents Q3 2019 · Dec 31, 2017 $859.83K
Current Liabilities Q3 2019 · Sep 30, 2019 $10.57M
Current Liabilities Q3 2019 · Dec 31, 2018 $7.06M
Total Liabilities Q3 2019 · Sep 30, 2019 $12.24M
Total Liabilities Q3 2019 · Dec 31, 2018 $8.61M
Current Assets Q3 2019 · Sep 30, 2019 $11.67M
Current Assets Q3 2019 · Dec 31, 2018 $12.39M
Total Assets Q3 2019 · Sep 30, 2019 $54.29M
Total Assets Q3 2019 · Dec 31, 2018 $49.69M
Stockholders Equity Q3 2019 · Jun 30, 2019 $42.68M
Stockholders Equity Q3 2019 · Mar 31, 2019 $42.49M
Stockholders Equity Q3 2019 · Sep 30, 2018 $45.19M
Stockholders Equity Q3 2019 · Jun 30, 2018 $47.16M
Stockholders Equity Q3 2019 · Mar 31, 2018 $46.88M
Stockholders Equity Q3 2019 · Dec 31, 2017 $45.17M
Shares Diluted Q3 2019 · Sep 30, 2018 52.02M sh
Shares Diluted Q3 2019 · Sep 30, 2018 54.81M sh
Operating Cash Flow Q3 2019 · Sep 30, 2018 $30.26M
Eps Diluted Q3 2019 · Sep 30, 2018 −$0.01
Eps Diluted Q3 2019 · Sep 30, 2018 $0.03
Eps Basic Q3 2019 · Sep 30, 2018 −$0.01
Eps Basic Q3 2019 · Sep 30, 2018 $0.03
Sga Expense Q3 2019 · Sep 30, 2018 $248.92K
Sga Expense Q3 2019 · Sep 30, 2018 $731.1K
Net Income Q3 2019 · Sep 30, 2018 −$380.82K
Net Income Q3 2019 · Sep 30, 2018 $1.38M
Operating Income Q3 2019 · Sep 30, 2018 $1.21M
Operating Income Q3 2019 · Sep 30, 2018 $3.5M
Gross Profit Q3 2019 · Sep 30, 2018 $1.46M
Gross Profit Q3 2019 · Sep 30, 2018 $5.3M
Cost Of Revenue Q3 2019 · Sep 30, 2018 $12.57M
Cost Of Revenue Q3 2019 · Sep 30, 2018 $26.59M